Predicting recurrence of nonfunctioning pituitary adenomas

Tae Woong Noh, Jae Jeong Hyeong, Mi Kyung Lee, Seung Kim Tai, Ho Kim Sun, Eunjig Lee

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Context: Nonfunctioning pituitary adenomas are commonly diagnosed as large tumors. Most are detected incidentally during imaging studies or as a result of neurological manifestations. Depending on severity, most patients with large tumors require surgery and adjunctive therapies because of the high rate of tumor recurrence. The ability to predict the recurrence of a tumor at the time of the initial surgery would be helpful in deciding whether adjunctive therapy is necessary and decreasing morbidity. We investigated the use of several cellular markers for predicting the recurrence of nonfunctioning pituitary adenomas. Objective: A tissue array block was made using tissue from 35 cases of nonfunctioning pituitary adenomas (16 cases with early recurrence ≤4 yr after surgery, 10 cases with late recurrence >4 yr after surgery, and nine cases without recurrence). Levels of tumor tissue cellular markers associated with cell proliferation or apoptosis were analyzed, and immunohistochemical study of cellular markers was conducted using sectioned slides from the tissue array block. Results: High Ki-67 and TUNEL labeling indexes were associated with recurrent nonfunctioning pituitary adenomas. Tumors with a high level of expression of phospho-Akt, phospho-p44/42 MAPK, and PTTG1 were associated with early recurrence. However, high levels of expression of phospho-CREB and ZAC1 were inversely associated with recurrence. Conclusions: Tumors with high levels of expression of phospho-Akt and phospho-p44/42MAPK and low levels of expression of phospho-CREB and ZAC1 should be followed closely and may require adjunctive therapy to prevent tumor recurrence.

Original languageEnglish
Pages (from-to)4406-4413
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number11
DOIs
Publication statusPublished - 2009 Jan 1

Fingerprint

Pituitary Neoplasms
Tumors
Recurrence
Surgery
Neoplasms
Tissue
Cell proliferation
Mitogen-Activated Protein Kinase 3
In Situ Nick-End Labeling
Labeling
Neurologic Manifestations
Therapeutics
Apoptosis
Imaging techniques
Cell Proliferation
Morbidity

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Noh, Tae Woong ; Hyeong, Jae Jeong ; Lee, Mi Kyung ; Tai, Seung Kim ; Sun, Ho Kim ; Lee, Eunjig. / Predicting recurrence of nonfunctioning pituitary adenomas. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 11. pp. 4406-4413.
@article{7a3d474dea564c0bb22fecd003710fb0,
title = "Predicting recurrence of nonfunctioning pituitary adenomas",
abstract = "Context: Nonfunctioning pituitary adenomas are commonly diagnosed as large tumors. Most are detected incidentally during imaging studies or as a result of neurological manifestations. Depending on severity, most patients with large tumors require surgery and adjunctive therapies because of the high rate of tumor recurrence. The ability to predict the recurrence of a tumor at the time of the initial surgery would be helpful in deciding whether adjunctive therapy is necessary and decreasing morbidity. We investigated the use of several cellular markers for predicting the recurrence of nonfunctioning pituitary adenomas. Objective: A tissue array block was made using tissue from 35 cases of nonfunctioning pituitary adenomas (16 cases with early recurrence ≤4 yr after surgery, 10 cases with late recurrence >4 yr after surgery, and nine cases without recurrence). Levels of tumor tissue cellular markers associated with cell proliferation or apoptosis were analyzed, and immunohistochemical study of cellular markers was conducted using sectioned slides from the tissue array block. Results: High Ki-67 and TUNEL labeling indexes were associated with recurrent nonfunctioning pituitary adenomas. Tumors with a high level of expression of phospho-Akt, phospho-p44/42 MAPK, and PTTG1 were associated with early recurrence. However, high levels of expression of phospho-CREB and ZAC1 were inversely associated with recurrence. Conclusions: Tumors with high levels of expression of phospho-Akt and phospho-p44/42MAPK and low levels of expression of phospho-CREB and ZAC1 should be followed closely and may require adjunctive therapy to prevent tumor recurrence.",
author = "Noh, {Tae Woong} and Hyeong, {Jae Jeong} and Lee, {Mi Kyung} and Tai, {Seung Kim} and Sun, {Ho Kim} and Eunjig Lee",
year = "2009",
month = "1",
day = "1",
doi = "10.1210/jc.2009-0471",
language = "English",
volume = "94",
pages = "4406--4413",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

Predicting recurrence of nonfunctioning pituitary adenomas. / Noh, Tae Woong; Hyeong, Jae Jeong; Lee, Mi Kyung; Tai, Seung Kim; Sun, Ho Kim; Lee, Eunjig.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 11, 01.01.2009, p. 4406-4413.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predicting recurrence of nonfunctioning pituitary adenomas

AU - Noh, Tae Woong

AU - Hyeong, Jae Jeong

AU - Lee, Mi Kyung

AU - Tai, Seung Kim

AU - Sun, Ho Kim

AU - Lee, Eunjig

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Context: Nonfunctioning pituitary adenomas are commonly diagnosed as large tumors. Most are detected incidentally during imaging studies or as a result of neurological manifestations. Depending on severity, most patients with large tumors require surgery and adjunctive therapies because of the high rate of tumor recurrence. The ability to predict the recurrence of a tumor at the time of the initial surgery would be helpful in deciding whether adjunctive therapy is necessary and decreasing morbidity. We investigated the use of several cellular markers for predicting the recurrence of nonfunctioning pituitary adenomas. Objective: A tissue array block was made using tissue from 35 cases of nonfunctioning pituitary adenomas (16 cases with early recurrence ≤4 yr after surgery, 10 cases with late recurrence >4 yr after surgery, and nine cases without recurrence). Levels of tumor tissue cellular markers associated with cell proliferation or apoptosis were analyzed, and immunohistochemical study of cellular markers was conducted using sectioned slides from the tissue array block. Results: High Ki-67 and TUNEL labeling indexes were associated with recurrent nonfunctioning pituitary adenomas. Tumors with a high level of expression of phospho-Akt, phospho-p44/42 MAPK, and PTTG1 were associated with early recurrence. However, high levels of expression of phospho-CREB and ZAC1 were inversely associated with recurrence. Conclusions: Tumors with high levels of expression of phospho-Akt and phospho-p44/42MAPK and low levels of expression of phospho-CREB and ZAC1 should be followed closely and may require adjunctive therapy to prevent tumor recurrence.

AB - Context: Nonfunctioning pituitary adenomas are commonly diagnosed as large tumors. Most are detected incidentally during imaging studies or as a result of neurological manifestations. Depending on severity, most patients with large tumors require surgery and adjunctive therapies because of the high rate of tumor recurrence. The ability to predict the recurrence of a tumor at the time of the initial surgery would be helpful in deciding whether adjunctive therapy is necessary and decreasing morbidity. We investigated the use of several cellular markers for predicting the recurrence of nonfunctioning pituitary adenomas. Objective: A tissue array block was made using tissue from 35 cases of nonfunctioning pituitary adenomas (16 cases with early recurrence ≤4 yr after surgery, 10 cases with late recurrence >4 yr after surgery, and nine cases without recurrence). Levels of tumor tissue cellular markers associated with cell proliferation or apoptosis were analyzed, and immunohistochemical study of cellular markers was conducted using sectioned slides from the tissue array block. Results: High Ki-67 and TUNEL labeling indexes were associated with recurrent nonfunctioning pituitary adenomas. Tumors with a high level of expression of phospho-Akt, phospho-p44/42 MAPK, and PTTG1 were associated with early recurrence. However, high levels of expression of phospho-CREB and ZAC1 were inversely associated with recurrence. Conclusions: Tumors with high levels of expression of phospho-Akt and phospho-p44/42MAPK and low levels of expression of phospho-CREB and ZAC1 should be followed closely and may require adjunctive therapy to prevent tumor recurrence.

UR - http://www.scopus.com/inward/record.url?scp=70449135219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449135219&partnerID=8YFLogxK

U2 - 10.1210/jc.2009-0471

DO - 10.1210/jc.2009-0471

M3 - Article

C2 - 19820025

AN - SCOPUS:70449135219

VL - 94

SP - 4406

EP - 4413

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -